イベント

開催済みのイベント

第1回 AMED SCARDA「ワクチン開発のための世界トップレベル研究開発拠点の形成事業」合同シンポジウムを開催しました 

2024年1月31日 ~2月2日 国立京都国際会館

Presentation Awardの情報を掲載しました。
詳しくはこちら

February 2024 

ソウル大学理学部の大学生グループGLEAPの見学受け入れ

【日時】 2024年1月10日 9:30 - 11:30

【人数】 学生9名 引率教授1名


プログラム

Welcome Remarks  

Professor Jun-ichiro Inoue

 Presentations 

Research at the UTOPIA Center: Under the Japan Initiative for World-leading Vaccine Research and Development Centers 

Professor Yoshihiro Kawaoka (via ZOOM)

Vaccine R & D in UTOPIA/Japan: for 100 days mission

Professor Ken Ishii

 Virology Lab Tour 

Dr. Ryuta Uraki

 Presentations by Young Researchers 

Hide and Seek: The Herpes Simplex Virus's Strategy to Escape from the Human Immune System

Dr. Ayano Fukui

Virus Research from Cellular to Global Level

Professor Yuki Furuse

UTOPIA セミナー

開催日時:2024年1月18日(木)16時-

開催場所:東京大学医科学研究所1号館講堂

演題
Antibody responses to SARS-CoV-2 infection and vaccination

講師

Florian Krammer
Department of Microbiology
Icahn School of Medicine at Mount Sinai, New York, USA

概要
It is thought that mRNA-based vaccine-induced immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wanes quickly, based mostly on short-term studies. We analyzed the kinetics and durability of the humoral responses to SARS-CoV-2 infection and vaccination using >8,000 longitudinal samples collected over a three-year period in New York City. Upon primary immunization, participants with pre-existing immunity mounted higher antibody responses faster and achieved higher steady-state antibody titers than naïve individuals. Antibody kinetics were characterized by two phases: an initial rapid decay followed by a stabilization phase with very slow decay. Booster vaccination equalized the differences in antibody levels between participants with and without hybrid immunity, but the antibody titers reached decreased with each successive antigen exposure. Breakthrough infections increased antibodies to similar titers as an additional vaccine dose in naïve individuals. Our study provides strong evidence that SARS-CoV-2 antibody responses are long- lasting, with initial waning followed by stabilization. In addition, this talk will also focus on the breadth of the induced antibody responses beyond SARS-CoV-2, mucosal immune responses, the functionality of non-neutralizing antibodies and development of novel vectored SARS-CoV-2 vaccines.

世話人:河岡義裕

Kei Sato  佐藤佳

 The Institute of Medical Science, The University of Tokyo 

Wendy Barclay 

Virology, Infectious Disease, Imperial College London 

@第70回日本ウイルス学会学術集会 

国際シンポジウム
ワクチン開発のイノベーション:世界の研究リーダーからの視点

@The 70th Annual Meeting of the Japanese Society for Virology

Symposium:
Innovation in vaccine development: Perspectives from global research leaders 

2023年9月26日  仙台 

Ralph S Baric 

The University of North Carolina at Chapel Hill 

Yoshihiro Kawaoka  河岡義裕

National Center for Global Health and Medicine
The University of Tokyo
University of Wisconsin-Madison 

Keiji Itaka  位髙啓史

Center for Infectious Disease Education and Research (CiDER), Osaka University
Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University 

ワクチンを100日で届けるためのサイエンス

The 21st Awaji International Forum on Infection and Immunity

Science for delivering vaccine in 100 days

2023年9月3-6日 長野(Hybrid形式)

UTOPIA シンポジウム

2023年6月10 - 11日 長野

UTOPIA International Kick-off Meeting

2023年3月29-30日 Web

UTOPIA キックオフ・シンポジウム

2022年11月5-6日 東京